On December 18th, the National Medical Products Administration of China approved Eli Lilly and Company's (hereinafter referred to as "Eli Lilly") Alzheimer's disease therapy, JiNengda&Co; reg; (Donaimab injection, intravenous infusion once every four weeks) is used to treat mild cognitive impairment and Alzheimer's disease mild dementia in adults caused by Alzheimer's disease.
It is reported that Ji Nengda& reg; It is the only targeted amyloid therapy with evidence supporting discontinuation after clearing amyloid plaques, which can help patients reduce treatment burden by reducing infusion frequency and treatment costs. After the United States, Japan, and the United Kingdom, China has approved the use of Minolta; reg; Another major market for listing.
It is estimated that 32 million people worldwide suffer from Alzheimer's disease dementia and have confirmed pathological changes in amyloid protein. There are currently nearly 9.83 million Alzheimer's disease patients in China. Moreover, the ranking of total deaths caused by dementia in China has risen from the tenth place in 1990 to the fifth place in 2019. At the same time, Alzheimer's disease also brings a heavy economic burden to families and society. Research shows that in 2015, the average annual cost of Alzheimer's disease patients in China reached 1.1 trillion yuan, accounting for about 1.47% of the gross domestic product (GDP). It is estimated that the socio-economic cost of Alzheimer's disease patients in China will reach 3.2 trillion yuan by 2030 and 11.9 trillion yuan by 2050.
Today's approval marks an important milestone in our commitment to changing the treatment of Alzheimer's disease in China. Due to the accelerated aging of the population, Alzheimer's disease has become a significant medical burden in China. We hope to achieve this goal, "said De Helan, President and General Manager of Eli Lilly China; Providing patients with opportunities for early intervention can help slow down the progression of this serious disease
Wang Li, Senior Vice President of Eli Lilly Global and Head of Eli Lilly China's Center for Drug Development and Medical Affairs, said, "Just five months after obtaining the world's first market approval, JiNengda® As a Class 1 innovative drug, it has obtained market approval in China, which fully reflects the support of regulatory authorities for the priority review and approval of breakthrough therapeutic drugs, and also demonstrates Lilly's commitment to accelerating the provision of breakthrough therapies for Chinese patients